Marksans Pharma: Navigating Growth and Strategic Expansion in Q3 & 9M FY26

Marksans Pharma Ltd. has reported a resilient performance for the third quarter and nine-month period of fiscal year 2026, demonstrating healthy revenue growth and sustained margin expansion despite prevailing market challenges. The company achieved an all-time high operating revenue of ₹754.4 crore in Q3 FY26, marking a robust 10.6% year-on-year increase. For the nine-month period, the operating revenue stood at ₹2,094.8 crore, reflecting a 9.4% growth compared to the previous year. This performance underscores Marksans' steady execution across key markets and the positive impact of seasonal demand.

Geographically, the US and North American market continued to be a strong growth driver, contributing ₹412.4 crore to Q3 revenue, up 16.9% YoY. This growth was bolstered by robust order books and a seasonal uptick. The UK and Europe segment recorded ₹258.2 crore, remaining flat YoY as pricing pressures persisted but stabilized sequentially. Australia and New Zealand showed impressive growth, with revenue reaching ₹61.4 crore, a 30.1% YoY increase. The Rest of the World (RoW) segment contributed ₹22.4 crore, where the company maintains a cautious approach due to macroeconomic challenges and payment risks. Product-wise, Marksans' FY25 revenue composition highlights the dominance of its OTC segment at 74.1%, with Rx products making up the remaining 25.9%.

Marksans Pharma's profitability metrics also showed positive trends. Gross profit for Q3 FY26 grew by 14.3% YoY to ₹438.2 crore, with the gross margin expanding to 58.1% from 56.2% last year. This improvement is attributed to softening raw material prices, a favorable product mix, and benefits from foreign exchange movements. EBITDA for the quarter increased by 23.2% YoY to ₹160.7 crore, with the EBITDA margin reaching 21.3%, an expansion of 217 basis points YoY and 125 basis points QoQ. This growth was primarily driven by operating leverage and improved cost efficiencies, particularly from the acquired Teva facility, which is now contributing significantly to operating leverage.

However, the nine-month EBITDA remained broadly flat at ₹405.4 crore, with margin moderation reflecting the impact of a weaker Q1, higher employee expenses, and costs associated with scale-up and integration. Net profit for Q3 FY26 increased by 8.2% YoY to ₹113.7 crore, aided by favorable foreign exchange gains. For the nine-month period, net profit declined YoY to ₹271.0 crore, primarily due to the weaker EBITDA in early FY26, higher lease-related finance costs for new warehouse facilities in the US and UK, and lower other income.

Strategic Initiatives and Future Outlook

Marksans Pharma is actively pursuing several strategic initiatives to drive long-term growth and strengthen its global footprint. The company is focused on expanding its store brand OTC segment, aiming to capture a significant share of the multi-billion-dollar global OTC market, projected to reach $204 billion by 2025. Marksans' OTC segment has already demonstrated a strong CAGR of 21% from FY17-FY25, positioning it as a preferred low-cost store brand manufacturing partner.

Innovation and pipeline power remain central to Marksans' strategy, with a continued focus on R&D investments. The company boasts a robust product pipeline of over 100 products, with aggressive filings in the UK and development of niche and complex molecules for the European market. R&D spend is expected to remain between 2.5% to 3% of sales for the next year, ensuring a steady stream of new product launches.

Capacity Expansion and Global Footprint

To support its growth ambitions, Marksans is significantly scaling up its manufacturing capacity. The company plans to double its low-cost manufacturing capacity in India from 8 billion to 16 billion units, contributing to a total manufacturing capacity of 26 billion units per annum. This expansion includes enhancing the acquired Goa unit to produce tablets, hard capsules, ointments, liquids, and creams.

Marksans is also strategically expanding its global footprint through inorganic growth. The company has incorporated new subsidiaries in Europe (Ireland) and Canada, actively exploring M&A opportunities in these regions to establish front-end marketing and distribution capabilities. Management anticipates significant progress in Europe within the next 3-5 years. The company's strong cash balance of ₹824.2 crore as of December 2025 and debt-free status provide a solid foundation for these strategic acquisitions and expansions.

Management's Vision and Shareholder Value

Management has articulated clear financial targets, aiming to reach a revenue of ₹3,000 crore within a year and a milestone of ₹4,000 crore in the next 2-3 years (FY28 or FY29). Specific goals include doubling revenue in the US and North America to become a top 5 private label OTC company and being among the top 3 Indian pharmaceutical firms in the UK. The company emphasizes disciplined capital allocation, utilizing cash effectively for buybacks, dividends, and targeted acquisitions, all while consistently enhancing shareholder value. Marksans Pharma's Q3 and 9M FY26 performance reflects a company committed to sustainable growth, strategic expansion, and operational excellence, positioning itself strongly for future market leadership.